Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Study of IMCnyeso, HLA- A 0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A 0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer

Trial Profile

A Phase I/II Study of IMCnyeso, HLA- A 0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A 0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMCnyeso (Primary)
  • Indications Carcinoma; Malignant melanoma; Non-small cell lung cancer; Synovial sarcoma; Urogenital cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms ImmTAC
  • Sponsors Immunocore

Most Recent Events

  • 02 Jul 2021 Status changed from active, no longer recruiting to discontinued.
  • 12 Apr 2021 Planned End Date changed from 1 Apr 2021 to 1 May 2021.
  • 12 Apr 2021 Planned primary completion date changed from 1 Mar 2021 to 1 May 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top